Over-expression of miR-145 enhances the effectiveness of HSVtk gene therapy for malignant glioma

Cancer Letters

Volumn 320, Issue 1, 2012, Pages 72-80

  Lee, Sang Jin ^a   Kim, Seok Jun ^a   Seo, Hye Hyun ^a   Shin, Seung Pil ^a   Kim, Daehong ^a   Park, Chung Soo ^a   Kim, Kyung Tae ^a   Kim, Yun Hee ^a   Jeong, Jin Sook ^b   Kim, In Hoo ^a  

^a National Cancer Center   (South Korea)

^b Dong A University   (South Korea)

Author keywords

Adenovirus; Gene therapy; Glioma; HSVtk; miR 145

Indexed keywords

ADAM22 PROTEIN; ADENOVIRUS VECTOR; FASCN1 PROTEIN; HSVTK PROTEIN; MICRORNA; MICRORNA 145; MUCIN 1; OSTEONECTIN; PLASMINOGEN ACTIVATOR; PLAUR PROTEIN; PROTEIN; SLC7A5 PROTEIN; SPOCK3 PROTEIN; UNCLASSIFIED DRUG;

ADAM22 GENE; ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FASCN1 GENE; FEMALE; GENE; GENE EXPRESSION; GENE THERAPY; GLIOBLASTOMA; HSVTK GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLAUR GENE; PRIORITY JOURNAL; SLC7A5 GENE; SPOCK3 GENE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE THERAPY; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED BALB C; MICRORNAS; RNA, CATALYTIC; SIMPLEXVIRUS; TELOMERASE; THYMIDINE KINASE;

ADENOVIRIDAE; ANIMALIA;

EID: 84862779309     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.029     Document Type: Article

References (45)

1. Ullrich N.J., Pomeroy S.L. Molecular genetics of pediatric central nervous system tumors. Curr. Oncol. Rep. 2006, 8:423-429.
2. Stummer W., Nestler U., Stockhammer F., Krex D., Kern B.C., Mehdorn H.M., Vince G.H., Pichlmeier U. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J. Neurooncol. 2010.
3. Badie B., Drazan K.E., Kramar M.H., Shaked A., Black K.L. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol. Res. 1995, 17:209-216.
4. Cheney I.W., Johnson D.E., Vaillancourt M.T., Avanzini J., Morimoto A., Demers G.W., Wills K.N., Shabram P.W., Bolen J.B., Tavtigian S.V., Bookstein R. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 1998, 58:2331-2334.
5. Fueyo J., Gomez-Manzano C., Yung W.K., Liu T.J., Alemany R., Bruner J.M., Chintala S.K., Rao J.S., Levin V.A., Kyritsis A.P. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 1998, 50:1307-1315.
6. Saito R., Bringas J.R., Panner A., Tamas M., Pieper R.O., Berger M.S., Bankiewicz K.S. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res. 2004, 64:6858-6862.
7. Shewach D.S., Zerbe L.K., Hughes T.L., Roessler B.J., Breakefield X.O., Davidson B.L. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther. 1994, 1:107-112.
8. Pan D., Wei X., Liu M., Feng S., Tian X., Feng X., Zhang X. Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells. Neurol. Res. 2009, 32:502-509.
9. King G.D., Kroeger K.M., Bresee C.J., Candolfi M., Liu C., Manalo C.M., Muhammad A.K., Pechnick R.N., Lowenstein P.R., Castro M.G. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol. Ther. 2008, 16:682-690.
10. Kaliberova L.N., Krendelchtchikova V., Harmon D.K., Stockard C.R., Petersen A.S., Markert J.M., Gillespie G.Y., Grizzle W.E., Buchsbaum D.J., Kaliberov S.A. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther. 2009, 16:794-805.
11. Im S.A., Gomez-Manzano C., Fueyo J., Liu T.J., Ke L.D., Kim J.S., Lee H.Y., Steck P.A., Kyritsis A.P., Yung W.K. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 1999, 59:895-900.
12. Lammering G., Valerie K., Lin P.S., Mikkelsen R.B., Contessa J.N., Feden J.P., Farnsworth J., Dent P., Schmidt-Ullrich R.K. Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin. Cancer Res. 2001, 7:682-690.
13. Geoerger B., Grill J., Opolon P., Morizet J., Aubert G., Terrier-Lacombe M.J., Bressac De-Paillerets B., Barrois M., Feunteun J., Kirn D.H., Vassal G. Oncolytic activity of the E1B-55kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 2002, 62:764-772.
14. Okada N., Saito T., Masunaga Y., Tsukada Y., Nakagawa S., Mizuguchi H., Mori K., Okada Y., Fujita T., Hayakawa T., Mayumi T., Yamamoto A. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res. 2001, 61:7913-7919.
15. Jiang H., Gomez-Manzano C., Lang F.F., Alemany R., Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr. Gene Ther. 2009, 9:422-427.
16. Jeong J.S., Lee S.W., Hong S.H., Lee Y.J., Jung H.I., Cho K.S., Seo H.H., Lee S.J., Park S., Song M.S., Kim C.M., Kim I.H. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model. Clin. Cancer Res. 2008, 14:281-290.
17. Hong S.H., Jeong J.S., Lee Y.J., Jung H.I., Cho K.S., Kim C.M., Kwon B.S., Sullenger B.A., Lee S.W., Kim I.H. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. Mol. Ther. 2008, 16:74-80.
18. Kwon B.S., Jung H.S., Song M.S., Cho K.S., Kim S.C., Kimm K., Jeong J.S., Kim I.H., Lee S.W. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript. Mol. Ther. 2005, 12:824-834.
19. Trask T.W., Trask R.P., Aguilar-Cordova E., Shine H.D., Wyde P.R., Goodman J.C., Hamilton W.J., Rojas-Martinez A., Chen S.H., Woo S.L., Grossman R.G. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 2000, 1:195-203.
20. Fulci G., Dmitrieva N., Gianni D., Fontana E.J., Pan X., Lu Y., Kaufman C.S., Kaur B., Lawler S.E., Lee R.J., Marsh C.B., Brat D.J., van Rooijen N., Stemmer-Rachamimov A.O., Hochberg F.H., Weissleder R., Martuza R.L., Chiocca E.A. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 2007, 67:9398-9406.
21. Friedman A., Tian J.P., Fulci G., Chiocca E.A., Wang J. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res. 2006, 66:2314-2319.
22. Cowland J.B., Hother C., Gronbaek K. MicroRNAs and cancer. APMIS 2007, 115:1090-1106.
23. Ambros V. MicroRNAs: tiny regulators with great potential. Cell 2001, 107:823-826.
24. Kim V.N., Han J., Siomi M.C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 2009, 10:126-139.
25. Chua J.H., Armugam A., Jeyaseelan K. MicroRNAs: biogenesis, function and applications. Curr. Opin. Mol. Ther. 2009, 11:189-199.
26. Taft R.J., Pang K.C., Mercer T.R., Dinger M., Mattick J.S. Non-coding RNAs: regulators of disease. J. Pathol. 2010, 220:126-139.
27. Zeng Y. Principles of micro-RNA production and maturation. Oncogene 2006, 25:6156-6162.
28. Godlewski J., Nowicki M.O., Bronisz A., Nuovo G., Palatini J., De Lay M., Van Brocklyn J., Ostrowski M.C., Chiocca E.A., Lawler S.E. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 2010, 37:620-632.
29. Martello G., Rosato A., Ferrari F., Manfrin A., Cordenonsi M., Dupont S., Enzo E., Guzzardo V., Rondina M., Spruce T., Parenti A.R., Daidone M.G., Bicciato S., Piccolo S. A MicroRNA targeting dicer for metastasis control. Cell 2010, 141:1195-1207.
30. Migliore C., Petrelli A., Ghiso E., Corso S., Capparuccia L., Eramo A., Comoglio P.M., Giordano S. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 2008, 68:10128-10136.
31. Godlewski J., Newton H.B., Chiocca E.A., Lawler S.E. MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ 2010, 17:221-228.
32. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
33. Negrini M., Calin G.A. Breast cancer metastasis: a microRNA story. Breast Cancer Res. 2008, 10:203.
34. Zhu S., Wu H., Wu F., Nie D., Sheng S., Mo Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18:350-359.
35. Godlewski J., Bronisz A., Nowicki M.O., Chiocca E.A., Lawler S. microRNA-451: a conditional switch controlling glioma cell proliferation and migration. Cell Cycle 2010, 9:2742-2748.
36. Sachdeva M., Mo Y.Y. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010, 70:378-387.
37. Chiyomaru T., Enokida H., Tatarano S., Kawahara K., Uchida Y., Nishiyama K., Fujimura L., Kikkawa N., Seki N., Nakagawa M. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br. J. Cancer 2010, 102:883-891.
38. La Rocca G., Shi B., Badin M., De Angelis T., Sepp-Lorenzino L., Baserga R. Growth inhibition by microRNAs that target the insulin receptor substrate-1. Cell Cycle 2009, 8:2255-2259.
39. Sachdeva M., Mo Y.Y. miR-145-mediated suppression of cell growth, invasion and metastasis. Am. J. Transl. Res. 2010, 2:170-180.
40. Sachdeva M., Zhu S., Wu F., Wu H., Walia V., Kumar S., Elble R., Watabe K., Mo Y.Y. P53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. USA 2009, 106:3207-3212.
41. Chivukula R.R., Mendell J.T. Abate and switch: miR-145 in stem cell differentiation. Cell 2009, 137:606-608.
42. Xu N., Papagiannakopoulos T., Pan G., Thomson J.A., Kosik K.S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009, 137:647-658.
43. Denduluri N., Low J.A., Lee J.J., Berman A.W., Walshe J.M., Vatas U., Chow C.K., Steinberg S.M., Yang S.X., Swain S.M. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol. 2007, 25:3421-3427.
44. Vile R.G., Diaz R.M., Castleden S., Chong H. Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells. Biochem. Soc. Trans. 1997, 25:717-722.
45. Sandmair A.M., Loimas S., Puranen P., Immonen A., Kossila M., Puranen M., Hurskainen H., Tyynela K., Turunen M., Vanninen R., Lehtolainen P., Paljarvi L., Johansson R., Vapalahti M., Yla-Herttuala S. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 2000, 11:2197-2205.